Comparison of an Acceleromyography- and Electromyography-based Neuromuscular Monitor With
A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effects after removal of the endotracheal tube. Unfortunately, the most widely used monitoring technique acceleromyography (AMG) typically implies a series of cumbers
| Condition(s) | Neuromuscular Blockade |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effects after removal of the endotracheal tube. Unfortunately, the most widely used monitoring technique acceleromyography (AMG) typically implies a series of cumbersome installation and calibration procedures that frequently precludes correct use of these devices in clinical practice. Electromyography (EMG) has recently attracted a lot of attention as an alternative strategy to compensate for the deficiency of AMG-based neuromuscular monitors. Nowadays, a new technology that allows for the simultaneous acquisition of EMG and AMG signals is commercially available. Although its reliability has been rapidly accepted in Physical Medicine and |
| Who can participate | Inclusion Criteria: * Age less than 18 yr * American Society of Anesthesiologists Physical Status I to III * Elective surgery requiring muscle relaxation * Patients participated voluntarily and signed informed consent Exclusion Criteria: * Patients with known neuromuscular disorder * Stroke * Patients with a history of allergic reaction toneuromuscular blocking agents * Use of medications that might interfere with neuromuscular transmission * Any previous injury to the examined arm that might influence nerve conduction parameters * Pacemaker |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Lead sponsor | Huazhong University of Science and Technology |
| Locations | Wuhan, Hubei, China; Wuhan, Hubei, China |
| Start date | 2023-03-01 |
| NCT ID | NCT05632107 |
| Official listing | https://clinicaltrials.gov/study/NCT05632107 |